Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study

摘要: Abstract Background: The emergence of multidrug-resistant nosocomial pathogens, such as Pseudomonas aeruginosa and Acinetobacter baumannii , has led to the revival systemic use antimicrobial agent colistin in critically ill patients, but only limited data are available define its pharmacokinetic profile these patients. Objective: aim this study was assess steady-state serum concentrations after IV administration methanesulfonate (CMS) patients with stable kidney function. Methods: This prospective, open-label, uncontrolled conducted at 2 intensive care units Athens Trauma Hospital, KAT, Athens, Greece. Adult were nonconsecutively enrolled if they had function ( Results: Fourteen nonconsecutive (13 male, 1 female; mean [SD] age, 62.0 [19.2] years; estimated weight, 72.5 [8.5] kg; Acute Physiology And Chronic Health Evaluation II score on admission, 17.1 [6.0]). At steady state, (SD) maximum minimum 2.93 (1.24) 1.03 (0.44) mg/L, respectively, while apparent total body clearance, volume distribution, t1/2 13.6 (5.8) L/h, 139.9 (60.3) L, 7.4 (1.7) hours, respectively. Colistin-related nephrotoxicity not observed Conclusion: CMS dosage regimens administered adult associated suboptimal Cmax/MIC ratios for many strains gram-negative bacilli currently reported sensitive (MIC, ≤2 μg/mL).